drugset / Trial / NCT04712097
A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma
RandomizedParallel-groupOpen-labelTreatment
Summary
This study will evaluate the efficacy and safety of mosunetuzumab in combination with lenalidomide (M + Len) compared to rituximab in combination with lenalidomide (R + Len) in participants with relapsed or refractory (R/R) follicular lymphoma (FL) who have received at least one line of prior systemic therapy.
Timeline
- Start
- 2021-10-27
- Primary completion
- 2026-06-03
- Completion
- 2029-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Mosunetuzumab | Monoclonal antibody | — | Intravenous |
| Subject | Rituximab | Monoclonal antibody | — | Intravenous |
| Background | Lenalidomide | Other / unclassified | — | Oral |
| Background | Tocilizumab | Monoclonal antibody | — | — |